CAS 1260075-17-9

Mitapivat

Description:

Mitapivat is a small molecule drug primarily used in the treatment of certain types of hemolytic anemia, particularly pyruvate kinase deficiency. It acts as a pyruvate kinase activator, enhancing the glycolytic pathway and promoting red blood cell survival by improving energy metabolism. The chemical structure of Mitapivat includes a pyrimidine core, which is essential for its biological activity. It is characterized by its ability to increase ATP production in red blood cells, thereby alleviating symptoms associated with anemia. Mitapivat is administered orally and has been shown to have a favorable pharmacokinetic profile, with a relatively long half-life that allows for once-daily dosing. Its safety and efficacy have been evaluated in clinical trials, demonstrating significant improvements in hemoglobin levels and overall patient quality of life. As with any medication, potential side effects may include headache, fatigue, and gastrointestinal disturbances, necessitating monitoring during treatment. Overall, Mitapivat represents a novel therapeutic approach for managing hemolytic anemia linked to pyruvate kinase deficiency.

Formula: C₂₄H₂₆N₄O₃S

Synonyms:

• N-(4-{[4-(Cyclopropylmethyl)-1-piperazinyl]carbonyl}phenyl)-8-quinolinesulfonamide
• N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
• PKM2 activator 1020
• CS-2722
• 8-Quinolinesulfonamide, N-[4-[[4-(cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-
• MITAPIVAT;PKM2 ACTIVATOR;CAS 1260075-17-9
• AG-348
• PKR-IN-1
• cas 1260075-17-9
• AG348;AG348;AG-348
• PKM2 activator
• ag348

Mitapivat

CAS: 1260075-17-9

Mitapivat

Purity: ≥98%

Molecular weight: 450.55g/mol

Ref: 54-BUP05143

Mitapivat

CAS: 1260075-17-9

Formula: C₂₄H₂₆N₄O₃S

Molecular weight: 450.56

Ref: 4Z-M-307001

Mitapivat-d8

CAS: 1260075-17-9

Formula: C₂₄H₁₈D₈N₄O₃S

Molecular weight: 458.61

Ref: 4Z-M-307002

Mitapivat

CAS: 1260075-17-9

Mitapivat (PKR-IN-1), also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.

Formula: C₂₄H₂₆N₄O₃S

Purity: 99.47% - 99.83%

Color and Shape: Solid

Molecular weight: 450.55

Ref: TM-T4223

Mitapivat

CAS: 1260075-17-9

Formula: C₂₄H₂₆N₄O₃S

Color and Shape: Neat

Ref: TR-M299830

Mitapivat

CAS: 1260075-17-9

Mitapivat is an aromatase inhibitor that has been shown to be effective in the treatment of breast cancer. It is administered orally and inhibits the production of estrogen. Mitapivat has been shown to have a specific effect on epithelial-mesenchymal transition in cancer tissues, which may contribute to its anticancer activity. Mitapivat also has pharmacological activity, such as inhibiting the production of lipids and proteins in the liver. Mitapivat can also cause adverse effects on red blood cells and renal function, including a decrease in glomerular filtration rate. The drug causes changes in redox potential and energy metabolism, leading to an increase in atp levels and a reduction in blood disorders. In vivo studies have shown that mitapivat can inhibit tumor growth by suppressing protein synthesis, cell proliferation, and angiogenesis.

Formula: C₂₄H₂₆N₄O₃S

Purity: Min. 95%

Molecular weight: 450.55 g/mol

Ref: 3D-KAC07517